Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170884-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
| Ab170884-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $297.90 | |
| Ab170884-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $747.90 | |
| Ab170884-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,197.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Efalizumab (anti-ITGAL) - Primary antibody, specific to ITGAL, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Lymphocyte function associated antigen, type 1, alpha subunit antibody; Antigen CD11A (p180), lymphocyte function associated antigen 1, alpha polypeptide antibody; Antigen CD11A antibody; CD 11a antibody; CD11 antigen-like family member A antibody; CD11a |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | ITGAL |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Integrin alpha-L/beta-2 (LFA-1) inhibitor |
| Product Description | Efalizumab (anti-ITGAL) is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab (anti-ITGAL) inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 27.4 kDa (Light Chain) & 51.6 kDa (Heavy Chain), under reducing conditions; 176.6 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 214745-43-4 |
Efalizumab (anti-ITGAL) (Ab170884) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling ITGAL (red) with Efalizumab (anti-ITGAL) (Ab170884). Goat Anti-Human IgG (FITC) (Ab175834) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Efalizumab (anti-ITGAL) (Ab170884) - SEC
The purity of Efalizumab (anti-ITGAL) (Ab170884) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001294 | Certificate of Analysis | Oct 13, 2023 | Ab170884 |
| ZJ23F1001295 | Certificate of Analysis | Oct 13, 2023 | Ab170884 |
| 1. Lin Kc, Ateeq HS, Hsiung SH, Chong LT, Zimmerman CN, Castro A, Lee WC, Hammond CE, Kalkunte S, Chen LL et al.. (1999) Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.. J Med Chem, 42 (5): (920-34). [PMID:10072689] |
| 2. Yenari MA, Kunis D, Sun GH, Onley D, Watson L, Turner S, Whitaker S, Steinberg GK. (1998) Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia.. Exp Neurol, 153 (2): (223-33). [PMID:9784282] |
| 3. Burdick DJ, Paris K, Weese K, Stanley M, Beresini M, Clark K, McDowell RS, Marsters JC, Gadek TR.. (2003) N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship.. Bioorg Med Chem Lett, 13 (6): (1015-1018). [PMID:12643901] |
| 4. Pei Z, Xin Z, Liu G, Li Y, Reilly EB, Lubbers NL, Huth JR, Link JT, von Geldern TW, Cox BF, Leitza S, Gao Y, Marsh KC, DeVries P, Okasinski GF.. (2001) Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides.. J Med Chem, 44 (18): (2913-2920). [PMID:11520199] |
| 5. Zhong M, Shen W, Barr KJ, Arbitrario JP, Arkin MR, Bui M, Chen T, Cunningham BC, Evanchik MJ, Hanan EJ, Hoch U, Huen K, Hyde J, Kumer JL, Lac T, Lawrence CE, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.. (2010) Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.. Bioorg Med Chem Lett, 20 (17): (5269-5273). [PMID:20655213] |
| 6. San Sebastián E, Zimmerman T, Zubia A, Vara Y, Martin E, Sirockin F, Dejaegere A, Stote RH, Lopez X, Pantoja-Uceda D, Valcárcel M, Mendoza L, Vidal-Vanaclocha F, Cossío FP, Blanco FJ.. (2013) Design, synthesis, and functional evaluation of leukocyte function associated antigen-1 antagonists in early and late stages of cancer development.. J Med Chem, 56 (3): (735-747). [PMID:23339734] |
| 7. Larson, R S RS, Corbi, A L AL, Berman, L L and Springer, T T.. (1989) Primary structure of the leukocyte function-associated molecule-1 alpha subunit: an integrin with an embedded domain defining a protein superfamily.. The Journal of cell biology, [PMID:2537322] |
| 8. Qu, A A and Leahy, D J DJ.. (1995) Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta 2) integrin.. Proceedings of the National Academy of Sciences of the United States of America, (24): [PMID:7479767] |
| 9. Cornwell, R D RD, Gollahon, K A KA and Hickstein, D D DD.. (1993) Description of the leukocyte function-associated antigen 1 (LFA-1 or CD11a) promoter.. Proceedings of the National Academy of Sciences of the United States of America, (1): [PMID:8097887] |
| 10. Shelley, C S CS, Farokhzad, O C OC and Arnaout, M A MA.. (1993) Identification of cell-specific and developmentally regulated nuclear factors that direct myeloid and lymphoid expression of the CD11a gene.. Proceedings of the National Academy of Sciences of the United States of America, (1): [PMID:8099450] |
| 11. Nueda, A A, López-Cabrera, M M, Vara, A A and Corbí, A L AL.. (1993) Characterization of the CD11a (alpha L, LFA-1 alpha) integrin gene promoter.. The Journal of biological chemistry, (15): [PMID:8103515] |
| 12. Qu, A A and Leahy, D J DJ.. (1996) The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin.. Structure (London, England : 1993), (15): [PMID:8805579] |
| 13. Loftus, B J BJ and 18 more authors.. (1999) Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q.. Genomics, (15): [PMID:10493829] |
| 14. Kallen, J J and 8 more authors.. (1999) Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain.. Journal of molecular biology, (10): [PMID:10493852] |
| 15. Weitz-Schmidt, G G and 8 more authors.. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.. Nature medicine, [PMID:11385505] |
| 16. Ostermann, Georg G, Weber, Kim S C KS, Zernecke, Alma A, Schröder, Andreas A and Weber, Christian C.. (2002) JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes.. Nature immunology, [PMID:11812992] |
| 17. Shimaoka, Motomu M and 11 more authors.. (2003) Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation.. Cell, (10): [PMID:12526797] |
| 18. Katano, Harutaka H, Pesnicak, Lesley L and Cohen, Jeffrey I JI.. (2004) Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.. Proceedings of the National Academy of Sciences of the United States of America, (6): [PMID:15041742] |
| 19. Barber, Domingo F DF, Faure, Mathias M and Long, Eric O EO.. (2004) LFA-1 contributes an early signal for NK cell cytotoxicity.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:15356110] |
| 20. Martin, Joel J and 121 more authors.. (2004) The sequence and analysis of duplication-rich human chromosome 16.. Nature, (23): [PMID:15616553] |
| 21. Wellington, Keri K and Perry, Caroline M CM.. (2005) Efalizumab.. American journal of clinical dermatology, [PMID:15799683] |
| 22. Liao, James K JK and Laufs, Ulrich U.. (2005) Pleiotropic effects of statins.. Annual review of pharmacology and toxicology, [PMID:15822172] |
| 23. Fagerholm, Susanna C SC, Hilden, Tiina J TJ, Nurmi, Susanna M SM and Gahmberg, Carl G CG.. (2005) Specific integrin alpha and beta chain phosphorylations regulate LFA-1 activation through affinity-dependent and -independent mechanisms.. The Journal of cell biology, (21): [PMID:16301335] |
| 24. and Descamps, V V.. () [Efalizumab].. Annales de dermatologie et de venereologie, [PMID:17053736] |
| 25. Frampton, James E JE and Plosker, Greg L GL.. (2009) Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis.. American journal of clinical dermatology, [PMID:19170413] |
| 26. Wollscheid, Bernd B and 7 more authors.. (2009) Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.. Nature biotechnology, [PMID:19349973] |
| 27. Kristóf, Endre E and 5 more authors.. (2013) Novel role of ICAM3 and LFA-1 in the clearance of apoptotic neutrophils by human macrophages.. Apoptosis : an international journal on programmed cell death, [PMID:23775590] |
| 28. Kawamoto, Eiji E and 6 more authors.. (2016) LFA-1 and Mac-1 integrins bind to the serine/threonine-rich domain of thrombomodulin.. Biochemical and biophysical research communications, (13): [PMID:27055590] |
| 29. and Paton, D M DM.. (2016) Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.. Drugs of today (Barcelona, Spain : 1998), [PMID:27883115] |
| 30. Swaim, Caleb D CD, Scott, Ariella F AF, Canadeo, Larissa A LA and Huibregtse, Jon M JM.. (2017) Extracellular ISG15 Signals Cytokine Secretion through the LFA-1 Integrin Receptor.. Molecular cell, (2): [PMID:29100055] |
| 31. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352] |
